CBL0137 and NKG2A blockade: a novel immuno-oncology combination therapy for Myc-overexpressing triple-negative breast cancers.

Oncogene · 2025 · PMC11932921 · PMID 39706891

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In line with Opal staining results, flow cytometry profiling also showed a trend towards decreased percentage of T cells and NK cells in CBL0137-treated tumors compared to vehicle-treated tumors, although not statistically significant (Fig.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.